渤健Biogen（BIIB）2025年第四季度及全年财务业绩和业务更新报告「NASDAQ」（英文版）（32页）.pdf

1、Q4 AND FULL YEAR 2025 Q4 AND FULL YEAR 2025 FINANCIAL RESULTS AND BUSINESS UPDATEFINANCIAL RESULTS AND BUSINESS UPDATEFebruary 6,2026This presentation and discussions during this conference call contain forward-looking statements,relating to:our strategy and plans;potential of,and expectations for,o

2、ur commercial business and pipeline programs;capitalallocation and investment strategy;clinical development programs,clinical trials,and data readouts and presentations;regulatory discussions,submissions,filings,and approvals;the potential benefits,safety,and efficacy of ourand our collaboration par

3、tners products and investigational therapies;the anticipated benefits and potential of investments or acquisitions;optimization of our cost structure including our Fit for Growth program;the goal ofcreating long-term sustainable growth;the impact from potential tariffs;productivity of our R&D pipeli

4、ne,collaborations,and business development activities;our future financial and operating results;and our full year 2026financial guidance.These forward-looking statements may be accompanied by such words as“aim,”“anticipate,”“assume,”“believe,”“contemplate,”“continue,”“could,”“estimate,”“expect,”“fo

5、recast,”“goal,”“guidance,”“hope,”“intend,”“may,”“objective,”“outlook,”“plan,”“possible,”“potential,”“predict,”“project,”“prospect,”“should,”“target,”“will,”“would,”and other words and terms of similar meaning.Drug development andcommercialization involve a high degree of risk,and only a small number

6、 of research and development programs result in commercialization of a product.Results in early-stage clinical trials may not be indicative of full results orresults from later stage or larger scale clinical trials and do not ensure regulatory approval.You should not place undue reliance on these st